China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed partner to advance the development of HAT001/HBM9013, a novel corticotropin releasing hormone (CRH) targeted therapy. The alliance aims to promote the drug’s development globally, excluding Greater China.
Agreement Details
Under the agreement, the partner will hold exclusive global rights to develop and commercialize HAT001/HBM9013, a potent anti-CRH-neutralizing antibody. Harbour BioMed is eligible to receive up to USD395 million, including upfront, milestone, and royalty payments, plus a warrant for a minority stake in the partner.
Drug Profile
HAT001/HBM9013 is designed to neutralize CRH for disorders like congenital adrenal hyperplasia (CAH). CAH, caused by mutations in adrenal hormone synthesis enzymes, has significant unmet medical needs. The drug has shown strong preclinical efficacy in downregulating CRH-mediated ACTH induction and is advancing toward clinical trials.-Fineline Info & Tech
Leave a Reply